west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "陈茂" 48 results
  • Research progress on the influence of fibrinogen on coronary heart disease

    The morbidity of coronary heart disease (CHD) is high, and the prognosis is unfavorable. Fibrinogen is both coagulation and inflammation factor, which has important influence on the occurrence and development of CHD. Previous studies reported that fibrinogen had relevance with traditional risk factors of CHD such as hypertension, diabetes and subclinical diseases such as left ventricular hypertrophy. The incidence of CHD increases with the fibrinogen level increasing. The fibrinogen level is higher in patients with CHD than that in healthy people. The coronary stenosis degree is heavier and the lesion is wider in patients with hyperfibrinogenemia. But the effects of fibrinogen on the secondary prevention of CHD is controversial. This paper summarized research progress based on the new understanding to fibrinogen on CHD recently.

    Release date:2018-03-26 03:32 Export PDF Favorites Scan
  • 人脱细胞生物羊膜治疗一例骨筋膜室综合征切开减压术后创面渗血

    目的 总结1例人脱细胞生物羊膜(human acellular amniotic membrane,HAAM)治疗全身抗凝患者骨筋膜室综合征切开减压术后创面渗血的疗效。方法 2012年6月收治1例74岁经皮冠状动脉介入治疗后9 h发生右臂骨筋膜室综合征的女性患者,因需持续全身抗凝治疗,给予硝酸甘油对症治疗及切开减压术后创面持续广泛渗血。立即停用硝酸甘油,HAAM覆盖创面,塔形敷料加压包扎。切开减压术后9 d肿胀消退,行创面缝合及大腿皮片游离植皮修复。结果 HAAM覆盖创面48 h后创面渗血停止。术后随访4个月,患者右前臂植皮区创面愈合良好,右手功能正常,前臂及手部皮肤感觉无异常。结论 HAAM结合塔形敷料加压包扎对控制创面广泛渗血有良好效果,但尚需进一步积累病例观察。

    Release date:2016-08-31 04:07 Export PDF Favorites Scan
  • 不适宜的左心室质量

    心血管疾病是严重危害人类健康的疾病之一,冠状动脉粥样硬化性心脏病、高血压、心肌肥厚、心力衰竭等疾病的发病率呈逐年上升趋势,临床上,正确地对心血管疾病进行风险分层具有重大意义。相较于正常左心室质量的人群而言,并非所有的左心室肥厚均会增加患者心血管不良事件(心肌梗死、卒中、室性心律失常、心力衰竭、心源性死亡等)的发生率。不适宜的左心室质量(iLVM),是指某一个体的左心室质量超过个人血流动力学负荷所能代偿部分的一种状态。iLVM不仅与左心室构型异常及心脏收缩及舒张功能障碍密切相关,而且预示了较高的心血管疾病风险。评估iLVM能够提高对患者潜在心血管疾病的识别能力并及时提示医生采取干预措施,有利于减缓及逆转左心室肥厚的发展,一定程度上减少不良心血管事件的发生,对于降低患者的心血管疾病的发病率和病死率,改善长期预后具有重要的临床意义。现就iLVM的研究进展进行综述。

    Release date: Export PDF Favorites Scan
  • Evidence-Based case report on the effect of TAVR on the severe aortic stenosis

    Objective To search and review the best clinical evidence to compare the clinical therapeutic effects and safety between TAVR and SAVR, thereby guiding its clinical use and providing references of treatments for such patients. Methods EMbase (1974~2016), MEDLINE (1996~2016) and The Cochrane Library (Issue 5, 2016) were systematically retrieved to collect randomized control trials, case-control studies and meta-analyses. Then, we assessed the quality of all the evidences to develop treatments based on those evidences and the situations of such patients. Results We identified 21 articles, including 2 articles of meta-analysis. With regard to the mortality and incidence of cardiovascular events, TAVR was not worse than SAVR. In addition, TAVR was more dominant than SAVR for patients who combined more basic diseases. Conclusion TAVR is one of the effective treatments for most patients with severe AS after sufficient assessment.

    Release date:2017-02-20 03:49 Export PDF Favorites Scan
  • 三酰甘油水平对冠状动脉粥样硬化性心脏病影响的研究进展

    冠状动脉粥样硬化性心脏病(冠心病)发病率高,预后差,是全球范围内导致死亡的主要原因之一。众所周知,高脂血症是冠心病的主要危险因素,目前多数研究主要聚焦于胆固醇和低密度脂蛋白水平对冠心病发病及预后的影响,而对于血脂中另一种成分—三酰甘油,对冠心病的影响研究相对较少。以往研究发现高三酰甘油血症患者冠心病发病率增加且预后不良;近期则研究报道了非空腹三酰甘油也与冠心病的发病及预后相关,同时发现高三酰甘油血症的影响在一些特殊人群(青年、女性)中尤为显著。基于最近对高三酰甘油血症在冠心病中的新认识,该文就三酰甘油水平对冠心病影响的研究进展进行了综述。

    Release date:2017-05-18 01:09 Export PDF Favorites Scan
  • The interpretation of 2017 ESC/EACTs and AHA/ACC guidelines for the management of valvular heart disease

    Release date:2017-11-21 03:49 Export PDF Favorites Scan
  • Interpretation of 2015 Experts Consensus for Transcatheter Aortic Valve Replacement

    Transcatheter aortic valve replacement (TAVR) developed rapidly since firstly introduced to clinical practice in 2002. In 2015, Experts Consensus for Transeatheter Aortic Valve Replacement (abbreviated as the Consensus) helped TAVR develop normatively and safely in China. This article interpreted the Consensus in combination of new evolutions of TAVR field: first, the indications of TAVR expand from inoperative and high risk patients to the intermediate risk patients; second, although the Consensus recommended pre-dilation with balloon of modest size, the necessity of pre-dilation is under debate; third, the Consensus pointed out main complications of TAVR, and the main strategies to avoid complications are careful pre-procedural analysis and development of new device; fourth, our experts had made outstanding contribution to TAVR in the treatment of patients with bicuspid aortic valve, which still has many problems to be solved urgently.

    Release date:2018-02-26 05:32 Export PDF Favorites Scan
  • Progress of transcatheter heart valve intervention

    At present, interventional therapy for structural heart disease is in a period of vigorous development. Among them, transcatheter aortic valve replacement, as a representative of the interventional treatment of heart valve disease, has made rapid progress, which is a bright spot in the field of cardiovascular disease. The future development of transcatheter tricuspid valve repair/replacement is also promising. With the availability of important clinical evidence, the indications of transcatheter aortic valve replacement have been extended to the full risk range of severe aortic stenosis. More and more data showed that transcatheter mitral and tricuspid valve interventions could effectively alleviate patients’ symptoms and improve their prognosis. Transcatheter valve interventions have developed rapidly and have made tremendous progress in China. This article will review and interpret the important progress in the field of transcatheter valve interventions.

    Release date:2020-05-26 02:34 Export PDF Favorites Scan
  • An interpretation of the 2-year follow-up results of Evolut Low Risk research

    Transcatheter aortic valve replacement (TAVR) has become a well-established treatment for patients with severe aortic stenosis. At present, TAVR has already shown noninferiority and even superiority to surgical aortic valve replacement (SAVR) in patients deemed at high or intermediate risk for SAVR. However, the long-term follow-up results of the randomized controlled trials comparing the efficacy and safety between TAVR and SAVR are still lacking in those patients who are at low risk for SAVR. This paper gives an overview and reviews results of the Evolut Low Risk trial and interprets its implications for transcatheter therapy in aortic valve diseases.

    Release date:2021-07-28 10:22 Export PDF Favorites Scan
  • Interpretation of Expert Consensus on Motor Rehabilitation after Transeatheter Aortic Valve Replacement

    At present, transeatheter aortic valve replacement is an effective treatment for elderly patients with severe aortic valve stenosis. Cardiac rehabilitation after transeatheter aortic valve replacement can effectively improve cardiopulmonary endurance and exercise capacity, and improve the quality of life. In order to better carry out cardiac rehabilitation for patients undergoing transeatheter aortic valve replacement, the Structural Heart Disease Professional Committee of Chinese College of Cardiovascular Physicians has drawn up Expert Consensus on Motor Rehabilitation after Transeatheter Aortic Valve Replacement. This consensus mainly elaborates the specific implementation process and methods of cardiac rehabilitation from three time periods of perioperative rehabilitation, outpatient rehabilitation and home rehabilitation. This article will interpret the main content of the consensus.

    Release date: Export PDF Favorites Scan
5 pages Previous 1 2 3 4 5 Next

Format

Content